In our clinical experience, before we started using chemo-immunotherapy, consistently with the reported outcomes of lung cancer patients with brain metastases [26], disease progression post-TKI is fast and the prognosis is less than 3 months with or without treatment; this is a population of high need, and, in our real-life daily practice, the benefit of ABCP was most noticeable here. Here, ABCG2 is linked to lung cancer.